Marquet Magda 4
4 · First Tracks Biotherapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
First Tracks (TRAX) Director Magda Marquet Receives 6,030 Shares
What Happened
- Magda Marquet, a director of First Tracks Biotherapeutics, received 6,030 shares on June 15, 2026 through the exercise/conversion of a derivative security (Code M). The acquisition price shown is $0.00 — these shares were settled from previously granted restricted stock units (RSUs) and no cash was paid at settlement.
Key Details
- Transaction date: June 15, 2026; Form 4 filed: June 17, 2026 (appears timely).
- Shares acquired: 6,030 shares; exercise/conversion price: $0.00 (no cash paid).
- Filing shows a corresponding conversion/disposition entry for the derivative instrument (standard when RSUs convert to common stock).
- Footnotes: F1 — each RSU converts to one share for no consideration; F2 — 100% of the RSUs vested on June 15, 2026 subject to continued service.
- Shares owned after the transaction are not specified in the excerpt provided.
Context
- This was not an open‑market purchase or a sale but the settlement of RSUs upon vesting; such transactions reflect compensation/vesting rather than a market bet by the insider. Code M indicates conversion/exercise of a derivative (here, RSUs converting into common stock).
Insider Transaction Report
Form 4
Marquet Magda
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-15+6,030→ 15,960 total - Exercise/Conversion
Restricted Stock Unit
[F1][F2]2026-06-15−6,030→ 0 total→ Common Stock (6,030 underlying)
Footnotes (2)
- [F1]Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Signature
/s/ Ajim Tamboli, Attorney-in-Fact|2026-06-17